Literature DB >> 9987756

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG).

D E Goodkin1, R L Priore, K E Wende, M Campion, D N Bourdette, R M Herndon, J S Fischer, L D Jacobs, D L Cookfair, R A Rudick, J R Richert, A M Salazar, C V Granger, J H Simon, J J Alam, D M Bartoszak, J Braiman, C M Brownscheidle, M E Coats, S L Cohan, D S Dougherty, R P Kinkel, M K Mass, F E Munschauer, R H Whitham.   

Abstract

We compared the ability of the Kurtzke Expanded Disability Status Scale (EDSS) and a composite outcome of non-physician-based measures of time to ambulate 25 feet (TA) and manual dexterity (the Box and Block Test [BBT], and 9-Hole Peg Test [9HPT]) to discriminate treatment effects in the Phase III study of interferon beta-1a. A log-rank comparison of Kaplan-Meier curves by treatment group showed the non-physician-based composite of BBT, 9HPT, and TA was of comparable sensitivity (P = 0.013) in discriminating sustained treatment failure as the EDSS alone (P = 0.029). The composite of BBT, 9HPT, TA, and EDSS was more sensitive (P = 0.009) in discriminating sustained treatment failure than the EDSS alone. Compositive outcomes of the EDSS and non-physician-based measures of manual dexterity and timed ambulation provide an appealing strategy to reduce the number of patients required to discriminate treatment effects in MS clinical trials.

Entities:  

Mesh:

Year:  1998        PMID: 9987756     DOI: 10.1177/135245859800400604

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  Measures of fine motor skills in people with tremor disorders: appraisal and interpretation.

Authors:  Kathleen E Norman; Martin E Héroux
Journal:  Front Neurol       Date:  2013-05-10       Impact factor: 4.003

2.  Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial.

Authors:  Paolo Zamboni; Antonio Bertolotto; Paolo Boldrini; Patrizia Cenni; Roberto D'Alessandro; Roberto D'Amico; Massimo Del Sette; Roberto Galeotti; Stefania Galimberti; Alessandro Liberati; Luca Massacesi; Donato Papini; Fabrizio Salvi; Silvana Simi; Andrea Stella; Luigi Tesio; Maria Grazia Valsecchi; Graziella Filippini
Journal:  Trials       Date:  2012-10-03       Impact factor: 2.279

3.  Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients.

Authors:  Emilia Sbardella; Nikolaos Petsas; Francesca Tona; Luca Prosperini; Eytan Raz; Gianvito Pace; Carlo Pozzilli; Patrizia Pantano
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.